Status
Conditions
Treatments
About
Prospective, interventional, non-randomized, open-label study, multi-center, Gehan-designed study with sequential inclusions in each subgroup, ranging from 4 subjects to a maximum 37 subjects per subgroup included
Full description
Retinal perfusion can be affected by a number of local or general pathologies; however, there is currently no commercially available device to provide accurate measurements of retinal blood flow. The company Quantel Medical is developing a medical imaging device HoloDoppler (hereinafter referred to as the "HoloDoppler system"). system. In order to better define its medical utility, we aim to evaluate its reproducibility and accuracy in healthy subjects and those with conditions that may affect ocular blood flow.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Criteria common to both populations ( patients and healthy volunteers) :
Criteria for healthy volunteers :
No ocular or systemic disease deemed to affect ocular circulation by an investigator
Specific criteria for patients:
Exclusion criteria
For all participants:
Persons covered by articles L1121-5 to L1121-8 of the CSP (all protected persons: pregnant women, parturients, nursing mothers, persons deprived of their liberty by judicial decision or administrative decision, minors, and persons under legal protection: guardianship or curatorship);
Women of childbearing age not using an effective method of contraception, or positive pregnancy test (blood or urine);
Participants allergic to tropicamide when using pupillary dilatation;
Inability of the subject to maintain a stable sitting position for research procedures;
Temporary contraindication to HoloDoppler:
Impossibility of making acquisitions of interest (e.g. due to a pupil diameter that is too small, advanced cataracts, nystagmus, etc.).
Wearing glasses or contact lenses to correct a refractive disorder is not considered a criterion for non-inclusion.
Primary purpose
Allocation
Interventional model
Masking
148 participants in 2 patient groups
Loading...
Central trial contact
Nabil BROUK
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal